PDF factsheet
      Z

cholesterol lowering intervention in diabetes type 2 for primary prevention, clinical trials results

atorvastatin versus placebo
ASCOT (diabetics sub group), 2003
10 mg atorvastatin
versus
placebo
hypertensive patients with no history of coronary heart disease (CHD) but at least three cardiovascular risk factors
ASPEN (primary prevention sub group), 2006
atorvastatin 10mg
versus
placebo
subjects with type 2 diabetes and LDL cholesterol levels below contemporary guideline targets; primary prevention subgroup double blind
Follow-up duration: 4 year
14 countries
CARDS, 2004
NCT00327418
atorvastatin 10mg/d
versus
placebo
patients with type 2 diabetes without high concentrations of LDL-cholesterol and at least one of the following: retinopathy, albuminuria, current smoking, or hypertension.double blind
Follow-up duration: 3.9 years
UK, Irelande
gemfibrozil versus placebo
HHS (diabetic sub group), 1987
gemfibrozil 600mg twice daily
versus
placebo
asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter double blind
lovastatin versus placebo
AFCAPS/TexCAPS (diabetic sub group), 1998
lovastatin
versus
placebo
men and women without clinically evident atherosclerotic cardiovascular disease with average total cholesterol (TC) and LDL-C levels and below-average high-density lipoprotein cholesterol (HDL-C) levelsdouble blind
pravastatin versus placebo
WOSCOPS (diabetic sub group), 1996
pravastatin 40 mg daily
versus
placebo
men aged 45-64 years with no history of myocardial infarction and plasma total cholesterol concentrations of 6.5-8.0 mmol/L at initial screeningdouble blind
Follow-up duration: mean 4.9y

  Options


in first

in second

  Filter